Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 10/20 | 0.55 |
| ▸ | GHSR | Q92847 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632618 | 0.94 | ACE (0.55) | ACEUTS2RECE1GHSR | |
| SCHEMBL30898976 | 0.94 | ACE (0.55) | ACEUTS2RECE1GHSR | |
| SCHEMBL29496441 | 0.91 | GHSR (0.65) | GHSR | |
| SCHEMBL29496564 | 0.91 | GHSR (0.65) | GHSR | |
| SCHEMBL30130571 | 0.90 | GHSR (0.59) | ACEUTS2RECE1GHSR | |
| SCHEMBL30422428 | 0.90 | ACE (0.62) | ACEECE1GHSR | |
| SCHEMBL30130563 | 0.90 | GHSR (0.59) | ACEUTS2RECE1GHSR | |
| SCHEMBL31619560 | 0.90 | IL23R (0.59) | UTS2RGHSR | |
| SCHEMBL31619561 | 0.90 | IL23R (0.59) | UTS2RGHSR | |
| SCHEMBL29972966 | 0.90 | IL23R (0.59) | UTS2RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3603648-B1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | SHIONOGI & CO (JP) | 2025-09-17 | — | — | EP | disclosed |
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | SHIONOGI & CO., LTD. (JP) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638717-B2 | Complex of nucleic acid medicine and multibranched lipid | FABP1, POLRMT, SREBF1 | ACE 1569/4885UTS2R 3115/4885ECE1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.